Meta-analysis of studies on the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11921-11931

  Nian, Xuewu ^a   Zhang, Wei ^a   Li, Limin ^a   Sun, Yan ^a   Sun, Erlin ^a   Han, Ruifa ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Gene polymorphism; Meta analysis; NF B1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ALLELE; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CAUCASIAN; DOMINANT GENE; ETHNICITY; GENE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC MODEL; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INDEL MUTATION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NUCLEAR FACTOR KAPPA B 1 GENE; PRIORITY JOURNAL; PROMOTER REGION; RECESSIVE GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; PUBLISHING; RISK;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; NEOPLASMS; NF-KAPPA B; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS;

EID: 84925284108     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2470-3     Document Type: Article

References (40)

1. Andersen V, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer. 2010;10:484.
2. Barnes PJ. Nuclear factor-kappa B. Int J Biochem Cell Biol. 1997;29:867–70.
3. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J. 2004;382:393–409.
4. Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol. 2007;133:859–66.
5. Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy. 2009;55:381–5.
6. Cai H, Sun L, Cui L, Cao Q, Qin C, et al. A functional insertion/deletion polymorphism (-94 ins/del ATTG) in the promoter region of the NFKB1 gene is related to the risk of renal cell carcinoma. Urol Int. 2013;91:206–12.
7. Cheng CW, Su JL, Lin CW, Su CW, Shih CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS ONE. 2013;8:e56130.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
9. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
10. Fan Y, Yu W, Ye P, Wang H, Wang Z, et al. NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol. 2011;30:241–5.
11. He Y, Zhang H, Yin J, Xie J, Tan X, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis. 2009;30:1916–22.
12. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
13. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35–45.
14. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.
15. Kim U, Gunther CS, Roeder RG. Genetic analyses of NFKB1 and OCA-B function: defects in B cells, serum IgM level, and antibody responses in Nfkb1−/−Oca-b−/− mice. J Immunol. 2000;165:6825–32.
16. Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, et al. Identification of the IGF1/PI3K/NFkB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 2013;13:549.
17. Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, et al. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol. 2007;42:1332–8.
18. Li P, Gu J, Yang X, Cai H, Tao J, et al. Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS ONE. 2013;8:e71604.
19. Lin CW, Hsieh YS, Hsin CH, Su CW, Lin CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PLoS ONE. 2012;7:e35078.
20. Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, et al. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243:47–54.
21. Lo SS, Chen JH, Wu CW, Lui WY. Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery. 2009;145:280–5.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
23. Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. Oncogene. 1993;8:191–3.
24. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55–62.
25. Mohd Suzairi MS, Tan SC, Ahmad Aizat AA, Mohd Aminudin M, Siti Nurfatimah MS, et al. The functional -94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. Cancer Epidemiol. 2013;37:634–8.
26. Oltulu YM, Coskunpinar E, Ozkan G, Aynaci E, Yildiz P, et al. Investigation of NF-kappaB1 and NF-kappaBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int. 2014;2014:530381.
27. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4:850–60.
28. Riemann K, Becker L, Struwe H, Nuckel H, Duhrsen U, et al. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics. 2006;16:783–8.
29. Riemann K, Becker L, Struwe H, Rubben H, Eisenhardt A, et al. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther. 2007;45:423–30.
30. Salim PH, Jobim M, Bredemeier M, Chies JA, Brenol JC, et al. Interleukin-10 gene promoter and NFKB1 promoter insertion/deletion polymorphisms in systemic sclerosis. Scand J Immunol. 2013;77:162–8.
31. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46:705–16.
32. Song S, Chen D, Lu J, Liao J, Luo Y, et al. NFkappaB1 and NFkappaBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS ONE. 2011;6:e21726.
33. Tang T, Cui S, Deng X, Gong Z, Jiang G, et al. Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol. 2010;29:9–12.
34. Ungerback J, Belenki D, Jawad ul-Hassan A, Fredrikson M, Fransen K, et al. Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis. 2012;33:2126–34.
35. Wang X, Lu P, Xu L, Xu Y, Shi Z, et al. Updated meta-analysis of NFkappaB1 -94ins/Delattg promoter polymorphism and cancer risk based on 19 case–control studies. Asia Pac J Cancer Prev. 2011;12:2479–84.
36. Zhang P, Wei Q, Li X, Wang K, Zeng H, et al. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet. 2009;191:73–7.
37. Zhou B, Qie M, Wang Y, Yan L, Zhang Z, et al. Relationship between NFKB1-94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Ann Oncol. 2010;21:506–11.
38. Zhou B, Rao L, Li Y, Gao L, Wang Y, et al. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett. 2009;275:72–6.
39. Zhou B, Rao L, Peng Y, Wang Y, Li Y, et al. Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy. BMC Med Genet. 2009;10:47.
40. Zou YF, Wang F, Feng XL, Tao JH, Zhu JM, et al. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens. 2011;77:9–17.